A Intravesical Brucella Abortus S19 (BAS19) Vaccine As A Potential Alternative To Bacillus Calmette-Guerin (BCG) Immunotherapy: A Preclinical Study In Rats
Urology Journal,
Vol. 23 No. 01 (2026),
29 Khordad 2026
,
Page 12-20
https://doi.org/10.22037/uj.v23i00.8561
Abstract
Purpose: This preliminary study aims to evaluate the immunogenicity and local immune response triggered by the intravesical administration of Brucella abortus S19 (BAS19) in a tumor-free rat model as a potential alternative to Bacillus Calmette-Guerin (BCG) in bladder cancer immunotherapy. The primary objective is to investigate immune activation and safety in the bladder, establishing a foundation for future studies assessing its therapeutic efficacy against urothelial carcinoma.
Materials and Methods: Nineteen female Wistar albino rats received intravesical BAS19 instillations and were euthanized after 3 and 6 weeks. Blood samples and cystectomy tissues were collected. The systemic immune response was assessed using the Rose Bengal agglutination test, immunocapture agglutination test, and blood cultures. Bladder tissues were examined histopathologically and stained immunohistochemically to evaluate local immune responses, specifically analyzing the expression of CD4, CD8, TLR4, and TNF-α.
Results: Higher Brucella-specific immunocapture titers and increased epithelial inflammation were observed in rats treated with BAS19 for 6 weeks. Moreover, significantly enhanced staining of CD4+, CD8+, and TNF-α in inflammatory cells was detected in this group. TLR4 expression was observed in all BAS19-treated rats, regardless of the exposure duration.
Conclusion: Intravesical BAS19 administration in rats induced strong local immune responses via CD4+, CD8+, TNF-α, and TLR4 expression without systemic toxicity. These results suggest that BAS19 may mimic BCG’s immunological pathways, particularly through TLR4 signaling. With its safety, low cost, and immunogenicity, BAS19 emerges as a promising immunotherapeutic candidate for further bladder cancer research.
- Bacillus Calmette-Guerin; blader cancer; Brucella abortus S19; immunotherapy; intravesical therapy; toll-like receptor 4
How to Cite
References
Sylvester RJ, Rodríguez O, Hernández V, et al. Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel" [Eur. Urol. 79(4) (2021) 480-488]. Eur Urol. 2023;83:e140-e1.
Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors. J Urol. 2017;197:S142-s5.
Gontero P, Birtle A, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update. Eur Urol. 2024;86:531-49.
Ourfali S, Ohannessian R, Fassi-Fehri H, Pages A, Badet L, Colombel M. Recurrence Rate and Cost Consequence of the Shortage of Bacillus Calmette-Guérin Connaught Strain for Bladder Cancer Patients. Eur Urol Focus. 2021;7:111-6.
Ohadian Moghadam S, Nowroozi MR. Toll-like receptors: The role in bladder cancer development, progression and immunotherapy. Scand J Immunol. 2019;90:e12818.
González-Reyes S, Marín L, González L, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer. 2010;10:665.
Tewari R, Choudhury SR, Ghosh S, Mehta VS, Sen E. Involvement of TNFα-induced TLR4-NF-κB and TLR4-HIF-1α feed-forward loops in the regulation of inflammatory responses in glioma. J Mol Med (Berl). 2012;90:67-80.
Park HD, Lee Y, Oh YK, et al. Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation. Oncogene. 2011;30:201-11.
Kimura T, Ishikawa H, Kojima T, et al. Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future. Jpn J Clin Oncol. 2020;50:1097-107.
Guo F, Das JK, Kobayashi KS, et al. Live attenuated bacterium limits cancer resistance to CAR-T therapy by remodeling the tumor microenvironment. J Immunother Cancer. 2022;10.
Dazord L, le Garrec Y, Bonnier M, Toujas L. Increased resistance to tumor graft in mice infected by vaccinal strains of Brucella abortus. Recent Results Cancer Res. 1980;75:92-9.
Torres N, Regge MV, Secchiari F, et al. Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein. J Immunother Cancer. 2020;8.
Dazord L, Le Garrec Y, David C, Toujas L. Resistance to transplanted cancer in mice increased by live Brucella vaccine. Br J Cancer. 1978;38:464-7.
Rossi AH, Farias A, Fernández JE, Bonomi HR, Goldbaum FA, Berguer PM. Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice. PLoS One. 2015;10:e0126827.
Darbandi A, Alamdary SZ, Koupaei M, Ghanavati R, Heidary M, Talebi M. Evaluation of immune responses to Brucella vaccines in mouse models: A systematic review. Front Vet Sci. 2022;9:903890.
Vershilova PA. The use of live vaccine for vaccination of human beings against brucellosis in the USSR. Bull World Health Organ. 1961;24:85-9.
Spink WW, Hall JW, 3rd, Finstad J, Mallet E. Immunization with viable Brucella organisms. Results of a safety test in humans. Bull World Health Organ. 1962;26:409-19.
Renoux G, Renoux M, Tinelli R. Phenol-water fractions from smooth Brucella abortus and Brucella melitensis: immunochemical analysis and biologic behavior. J Infect Dis. 1973;127:139-48.
Hou H, Liu X, Peng Q. The advances in brucellosis vaccines. Vaccine. 2019;37:3981-8.
Perkins SD, Smither SJ, Atkins HS. Towards a Brucella vaccine for humans. FEMS Microbiol Rev. 2010;34:379-94.
Han J, Gu X, Li Y, Wu Q. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed Pharmacother. 2020;129:110393.
Shintani Y, Sawada Y, Inagaki T, Kohjimoto Y, Uekado Y, Shinka T. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy. Int J Urol. 2007;14:140-6.
Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124-9.
Fankhauser CD, Teoh JY, Mostafid H. Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage. Curr Opin Urol. 2020;30:365-9.
Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63:462-72.
Li Y, Youssef SF, Buanz AB. Intravesical combination therapies for non-muscle invasive bladder cancer: Recent advances and future directions. Eur J Pharmacol. 2022;926:175024.
Packiam VT, Johnson SC, Steinberg GD. Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guérin. Cancer. 2017;123:390-400.
Narayan VM, Dinney CPN. Intravesical Gene Therapy. Urol Clin North Am. 2020;47:93-101.
Tholomier C, Martini A, Mokkapati S, Dinney CP. The current status of gene therapy in bladder cancer. Expert Rev Anticancer Ther. 2023;23:531-43.
Brooks NA, O'Donnell MA. Combination Intravesical Therapy. Urol Clin North Am. 2020;47:83-91.
- Abstract Viewed: 238 times
- 8561/pdf Downloaded: 42 times